journal article·2026-07-29

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

Jing Wu, Jiaxuan Chen, Abdechakour Elkihel, Wenjun Lan, Nicolas Fraunhoffer, Dandan Zhu, Baoping Lian, Christina Galanakou, Zhancun Bian, Xi Liu, Odile Gayet, Loic Moubri, Julie Aglietti Roques, Vikash Reebye, Nagy Habib, Xiaoxuan Liu, Nelson Dusetti, Juan Lucio Iovanna, Ling Peng

Publisher page

Abstract

ABSTRACT Nucleic acid therapeutics offer unique opportunities to develop personalized precision therapies by responding specifically and effectively at the gene level to evolving pathogens. However, many nucleic acid drugs employ a single‐target strategy, which is effective in monogenic disorders, yet can be ineffective in treating diseases characterized by complex and interacting molecular events. Nucleic acid combinations capable of simultaneously modulating multiple pathways and harnessing concerted effects constitute a promising approach to combatting complex, dynamically evolving and heterogeneous diseases. Here, we report a combination strategy utilizing small activating RNA to activate tumor suppressor genes alongside small interfering RNA to silence oncogenes for therapeutic potential and clinical relevance in cancer treatment using patient‐derived tumor models of pancreatic cancer. Transcriptomic and proteomic profiling of individual patient tumors enabled rational design of patient‐specific combinations, which exhibited superior anticancer efficacy through coordinated regulation of multiple genes. Importantly, diverse combinations were tailored to individual patient tumor models to elicit therapeutic responses, while certain specific combinations demonstrated therapeutic efficacy across different tumor models that shared similar genetic features, highlighting the flexibility and pan‐treatment potential. Our findings not only confirm the efficacy of the combination approach for cancer treatment, but also underscore its potential applicability to other complex malignancies.
Source: crossref · Quality: baseline

Affiliations

Aix Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325 Equipe Labellisée Ligue Contre le Cancer Marseille France

Aix Marseille University, CNRS, INSERM, Institut Paoli‐Calmettes CRCM Marseille France

State Key Laboratory of Natural Medicines, Joint International Research Laboratory of Target Discovery and New Drug Innovation (Ministry of Education), Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials China Pharmaceutical University Nanjing China

Center For Pharmacological and Botanical Studies, Faculty of Medicine, National Scientific and Technical Research Council University of Buenos Aires Buenos Aires Argentina

MiNA Therapeutics Ltd, Translation & Innovation Hub London UK

Department of Surgery and Cancer, Hammersmith Hospital Imperial College London London UK

Funding

China Scholarship Council

References (51)

Show source-provided references
1. Frameworks for Transformational Breakthroughs in RNA‐Based Medicines10.1038/s41573-024-00943-2 ↗
2. Author Correction: The Current Landscape of Nucleic Acid Therapeutics10.1038/s41565-021-00937-w ↗
3. Successes and Challenges in Clinical Gene Therapy10.1038/s41434-023-00390-5 ↗
4. The Current State and Future Directions of RNAi‐based Therapeutics10.1038/s41573-019-0017-4 ↗
5. RNAi‐Based Drug Design: Considerations and Future Directions10.1038/s41573-024-00912-9 ↗
6. Small Activating RNAs Lead the Charge to Turn up Gene Expression10.1038/d41573-021-00127-2 ↗
7. RNAa: Mechanisms, Therapeutic Potential, and Clinical Progress10.1016/j.omtn.2025.102494 ↗
8. Small dsRNAs Induce Transcriptional Activation in human Cells10.1073/pnas.0607015103 ↗
9. Therapeutic Developments in Pancreatic Cancer10.1038/s41575-023-00840-w ↗
10. Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes10.1038/nature11547 ↗
11. Whole Genomes Redefine the Mutational Landscape of Pancreatic Cancer10.1038/nature14169 ↗
12. Significance of TP53, CDKN2A, SMAD4, and KRAS in Pancreatic Cancer10.3390/cimb46040177 ↗
13. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer10.1056/NEJMoa2208470 ↗
14. Adagrasib: First Approval10.1007/s40265-023-01839-y ↗
15. The MYC Oncogene — The Grand Orchestrator of Cancer Growth and Immune Evasion10.1038/s41571-021-00549-2 ↗
16. MYC in Cancer: From Undruggable Target to Clinical Trials10.1038/s41573-025-01143-2 ↗
17. MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype10.1158/2159-8290.CD-19-0435 ↗
18. Amplification of AKT2 in human Pancreatic Cells and Inhibition of AKT2 Expression and Tumorigenicity by Antisense RNA10.1073/pnas.93.8.3636 ↗
19. Clinical Significance of AKT2 in Advanced Pancreatic Cancer Treated with Erlotinib10.3892/ijo.2017.3961 ↗
20. Survivin, Cancer Networks and Pathway‐Directed Drug Discovery10.1038/nrc2293 ↗
21. The Role of Survivin in the Progression of Pancreatic Ductal Adenocarcinoma (PDAC) and a Novel Survivin‐Targeted Therapeutic for PDAC10.1371/journal.pone.0226917 ↗
22. p21 in Cancer: Intricate Networks and Multiple Activities10.1038/nrc2657 ↗
23. c‐Myc Inhibition and p21 Modulation Contribute to Unsymmetrical Bisacridines‐induced Apoptosis and Senescence in Pancreatic Cancer Cells10.1007/s43440-024-00658-6 ↗
24. Targeted Delivery of C/EBPα‐saRNA by RNA Aptamers Shows Anti‐Tumor Effects in a Mouse Model of Advanced PDAC10.1016/j.omtn.2019.08.017 ↗
25. Targeted Delivery of C/EBPα ‐saRNA by Pancreatic Ductal Adenocarcinoma‐specific RNA Aptamers Inhibits Tumor Growth In Vivo10.1038/mt.2016.60 ↗
26. Targeted Delivery of C/EBPα‐small Activation RNA (saRNA) by RNA Aptamer Inhibits the Growth of Pancreatic Ductal Adenocarcinoma (PDAC) in Vivo10.1016/S1525-0016(16)33892-8 ↗
27. Phase I Multicenter Dose Escalation Study of DCR‐MYC in Patients With Solid Tumors Multiple Myeloma or Lymphoma. ClinicalTrials.gov. Identifier: NCT02110563 https://clinicaltrials.gov/study/NCT02110563. (accessed: August 2025).
28. Phase I Study of LY2181308, an Antisense Oligonucleotide Against Survivin, in Patients with Advanced Solid Tumors10.1007/s00280-010-1506-7 ↗
29. A Randomised Phase 2 Study Combining LY2181308 Sodium (survivin antisense oligonucleotide) with First‐line Docetaxel/Prednisone in Patients with Castration‐Resistant Prostate Cancer10.1016/j.eururo.2013.10.039 ↗
30. 10.1038/s41392‐024‐02112‐810.1038/s41392‐024‐02112‐8 ↗
31. TIMEPOINT, a Phase 1 Study Combining MTL‐CEBPA with Pembrolizumab, Supports the Immunomodulatory Effect of MTL‐CEBPA in Solid Tumors10.1016/j.xcrm.2025.102041 ↗
32. Radomised Phase II Study of MTL‐CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2) ClinicalTrials.govIdentifier: NCT04710641.https://clinicaltrials.gov/study/NCT04710641(accessed: August 2025).
33. Phase I Study of RNA Oligonucleotide MTL‐CEBPA Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma ClinicalTrials.govIdentifier: NCT05097911.https://clinicaltrials.gov/study/NCT05097911(accessed: August 2025).
34. Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG‐01 in Non‐Muscle Invasive Bladder Cancer https://www.ractigen.com/ractigen‐therapeutics‐announces‐china‐nmpa‐ind‐approval‐for‐phase‐ii‐clinical‐trial‐of‐sarna‐therapy‐rag‐01‐in‐non‐muscle‐invasive‐bladder‐cancer/(accessed: August 2025).
35. The Human Protein Atlas https://www.proteinatlas.org/ (accessed: January 2025).
36. Development of Transcriptomic Tools for Predicting the Response to Individual Drug of the mFOLFIRINOX Regimen in Patients with Metastatic Pancreatic Cancer10.3389/fonc.2024.1437200 ↗
37. Insights Into the Regulation of Protein Abundance From Proteomic and Transcriptomic Analyses10.1038/nrg3185 ↗
38. On the Dependency of Cellular Protein Levels on mRNA Abundance10.1016/j.cell.2016.03.014 ↗
39. Synthesis and Use of an Amphiphilic Dendrimer for siRNA Delivery Into Primary Immune Cells10.1038/s41596-020-00418-9 ↗
40. Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment10.1002/advs.202200562 ↗
41. Arginine‐terminated Generation 4 PAMAM Dendrimer as an Effective Nanovector for Functional siRNA Delivery in Vitro and in Vivo10.1021/bc4005156 ↗
42. The EPR Effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect10.1016/j.addr.2010.04.009 ↗
43. Cargo‐Selective and Adaptive Delivery of Nucleic Acid Therapeutics by Bola‐Amphiphilic Dendrimers10.1073/pnas.2220787120 ↗
44. Three‐Dimensional Organotypic Culture: Experimental Models of Mammalian Biology and Disease10.1038/nrm3873 ↗
45. Organoids in Cancer Research10.1038/s41568-018-0007-6 ↗
46. The Third Dimension Bridges the Gap Between Cell Culture and Live Tissue10.1038/nrm2236 ↗
47. Effects of 3D Culturing Conditions on the Transcriptomic Profile of Stem‐cell‐derived Neurons10.1038/s41551-018-0219-9 ↗
48. Screening Drug Effects in Patient‐Derived Cancer Cells Links Organoid Responses to Genome Alterations10.15252/msb.20177697 ↗
49. Dendrimer Nanosystems for Adaptive Tumor‐Assisted Drug Delivery via Extracellular Vesicle Hijacking10.1073/pnas.2215308120 ↗
50. Amphiphilic Dendrimer Vectors for RNA Delivery: State‐of‐the‐Art and Future Perspective10.1021/accountsmr.1c00272 ↗
51. Dendrimer Engineering to Overcome Delivery Challenges of Nucleic Acids10.1038/s44222-025-00347-w ↗